Eli Lilly 2004 Annual Report Download - page 79

Download and view the complete annual report

Please find page 79 of the 2004 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 100

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100

PROXY STATEMENT
7777
Performance Graph
This graph compares the return on Lilly stock with that of the Standard & Poor’s 500 Stock Index and our peer
group* for the years 2000 through 2004. The graph assumes that, on December 31, 1999, a person invested $100
each in Lilly stock, the S&P 500 Stock Index, and the peer group’s common stock. The graph measures total share-
holder return, which takes into account both stock price and dividends. It assumes that dividends paid by a com-
pany are reinvested in that company’s stock.
Comparison of Five-Year Cumulative Total Return Among Lilly, S&P 500 Stock Index, and Peer Group*
Value of $100 invested on last business day of 1999
Dec. 1999 Dec. 2000 Dec. 2001 Dec. 2002 Dec. 2003 Dec. 2004
1999 2000 2001 2002 2003 2004
Lilly $100.00 $141.74 $121.36 $100.10 $113.23 $93.44
S&P 500 $100.00 $ 90.89 $ 81.14 $ 62.47 $ 80.35 $89.07
Peer Group $100.00 $128.26 $110.98 $ 86.41 $ 94.96 $91.41
* We constructed the peer group as the industry index for this graph. It comprises the eight companies in the
pharmaceutical industry that we use to benchmark compensation of executive offi cers: Abbott Laboratories;
Bristol-Myers Squibb Company; Glaxo SmithKline (including the results of SmithKline Beecham plc up to the
time of its merger with Glaxo Holdings plc); Johnson & Johnson; Merck & Co.; Pfi zer, Inc. (including the results
of Warner Lambert Company and Pharmacia Corporation up to the time of their mergers with Pfi zer); Schering-
Plough Corporation; and Wyeth (formerly American Home Products Corporation).